Investigating Serum Endocannabinoid Levels in Mood Dysregulation

Bipolar disorder involves profound shifts in mood, energy, and cognitive functioning. Clinicians frequently encounter diagnostic and monitoring challenges because objective biological markers remain scarce in clinical psychiatry. Recently, researchers have highlighted the endocannabinoid system as an essential regulator of neurotransmission and emotional equilibrium. Specifically, evaluating alterations in serum endocannabinoid levels provides crucial insights into how neuroactive lipid mediators fluctuate across distinct affective phases. The endogenous lipid signaling network comprises classical endocannabinoids like anandamide and 2-arachidonoylglycerol, along with bioactive lipid congeners such as palmitoylethanolamide and oleoylethanolamide. These molecules modulate neuroinflammation, synaptic plasticity, and dopaminergic tone across major limbic pathways. Consequently, disturbances within this lipid cascade could drive the behavioral excitement and neurochemical instability that characterize acute mania. While previous cross-sectional studies suggested atypical circulating levels in mood pathology, they rarely examined patients prospectively across varying clinical states. Therefore, evaluating these specific biomarkers during acute episodes and subsequent stabilization addresses a vital knowledge gap. Understanding these biological dynamics offers substantial promise for identifying state-dependent psychiatric markers. Furthermore, this research expands our comprehension of the neurobiology underpinning bipolar disorder.

Clinical Study Design and Patient Evaluation Across Phases

To rigorously evaluate lipid signaling across illness trajectories, investigators conducted a well-controlled prospective clinical study. The research cohort included fifty-one adult patients presenting with an acute manic episode according to DSM-5-TR criteria. In addition, the researchers recruited forty-nine age- and sex-matched healthy control subjects to establish baseline biological reference parameters. Following acute psychiatric intervention and hospital discharge, clinicians successfully followed thirty-two patients into confirmed clinical remission. During each clinical visit, psychiatrists comprehensively assessed symptomatology using standardized psychiatric rating tools. Specifically, they utilized the Young Mania Rating Scale to measure manic severity, alongside the Hamilton Depression Rating Scale for depressive symptoms. Moreover, the team administered the Positive and Negative Syndrome Scale to document any concomitant psychotic manifestations. Concurrently, laboratory technicians drew venous blood samples from all participants to quantify circulating biochemical markers. The bioanalytical protocol measured serum palmitoylethanolamide, oleoylethanolamide, 2-arachidonoylglycerol, and anandamide. Additionally, clinicians recorded high-sensitivity C-reactive protein levels to account for systemic inflammatory activity. This within-patient longitudinal design allowed researchers to compare biological markers across active disease and euthymia directly.

Key Findings on Palmitoylethanolamide and Oleoylethanolamide Dynamics

The statistical analysis revealed remarkable stage-specific fluctuations in circulating lipid compounds. During acute manic episodes, patients demonstrated significantly lower serum palmitoylethanolamide and oleoylethanolamide concentrations than healthy controls. In contrast, the classic endocannabinoids anandamide and 2-arachidonoylglycerol exhibited no significant differences between the cohorts. Similarly, baseline systemic inflammatory markers remained broadly comparable between the groups. When clinicians evaluated patients during remission, a striking biological shift occurred. Specifically, serum levels of both palmitoylethanolamide and oleoylethanolamide normalized completely, reaching values indistinguishable from healthy control baselines. Furthermore, the researchers conducted pairwise within-patient comparisons between the acute manic episode and subsequent clinical remission. In this paired analysis, serum palmitoylethanolamide levels proved significantly lower during active mania than in remission. Meanwhile, oleoylethanolamide demonstrated a clear upward trend upon affective recovery, although only palmitoylethanolamide achieved formal statistical significance in paired testing. These empirical results confirm that peripheral concentrations of endogenous acylethanolamides reflect distinct affective states in bipolar disorder. Therefore, the transient depletion of these neuroprotective lipids appears inextricably linked to the acute manic phase.

Neurobiological Mechanisms Underlying Cannabinoid Tone in Mania

The biological underpinnings of these lipid fluctuations involve complex interactions across cellular and neuroinflammatory networks. Both palmitoylethanolamide and oleoylethanolamide act primarily through peroxisome proliferator-activated receptor-alpha rather than classical cannabinoid receptors. Through this nuclear pathway, palmitoylethanolamide potently suppresses microglial activation, reduces oxidative stress, and controls neuroinflammation. In addition, palmitoylethanolamide enhances anandamide activity through an established entourage effect, optimizing endogenous neuroprotective signaling. However, during acute mania, hyperdopaminergic neurotransmission and elevated cellular stress may accelerate the consumption or impair the biosynthesis of these bioactive lipids. Consequently, depleted acylethanolamide levels could fail to restrain central inflammatory cascades, exacerbating affective volatility and psychomotor agitation. Furthermore, oleoylethanolamide influences dopamine turnover and circadian rhythms, which suffer severe disruption during manic episodes. Thus, a sudden decline in oleoylethanolamide might compromise synaptic homeostasis within corticolimbic circuitry. Because peripheral acylethanolamides readily reflect central lipid metabolism, circulating serum levels provide an accessible window into brain neurochemistry. Importantly, clinical stabilization appears to restore enzymatic balance, allowing lipid mediator concentrations to recover.

Implications for Mood Stabilization and Future Biomarker Development

These clinical findings provide compelling evidence that lipid-signaling pathways participate directly in affective state transitions. For clinicians, identifying reliable state markers offers substantial practical value in psychiatric care. Currently, practitioners rely almost entirely on subjective behavioral evaluations to judge disease progression and remission status. However, measuring serum lipid mediators could eventually furnish objective biological confirmation of clinical recovery. In addition, these results create exciting opportunities for developing novel therapeutic interventions in bipolar disorder. Traditional pharmacotherapy primarily targets monoamine transporters and post-synaptic receptors, which often leaves residual cognitive or affective symptoms. Conversely, targeting the endocannabinoid and acylethanolamide system could offer complementary neuroprotective benefits without typical adverse effects. For instance, exogenous palmitoylethanolamide supplementation already demonstrates favorable safety profiles in neurological and pain disorders. Therefore, future clinical trials should investigate whether adjunctive palmitoylethanolamide administration can accelerate recovery during acute manic episodes. Furthermore, inhibiting fatty acid amide hydrolase, the enzyme responsible for acylethanolamide degradation, represents another plausible pharmacological avenue. While larger longitudinal studies must validate these findings across diverse demographic populations, this investigation marks a pivotal step forward. Ultimately, integrating lipidomics into mainstream psychiatry may transform diagnostic precision and targeted therapeutics for severe mood disorders.

How do endocannabinoid levels shift between mania and remission?

During acute manic episodes, circulating levels of palmitoylethanolamide and oleoylethanolamide drop significantly compared to healthy individuals. In contrast, classical endocannabinoids such as anandamide remain unchanged. When patients enter remission, however, these depleted acylethanolamides rebound completely to baseline healthy levels. Specifically, longitudinal within-patient evaluations confirm that palmitoylethanolamide levels rise significantly during clinical recovery. This dynamic pattern indicates that acylethanolamide deficiency represents a transient, state-dependent phenomenon rather than a permanent psychiatric trait.

What biological role does palmitoylethanolamide play in mood stability?

Palmitoylethanolamide acts primarily as an endogenous lipid mediator that targets peroxisome proliferator-activated receptor-alpha rather than classical cannabinoid receptors. Through this specific nuclear pathway, the molecule suppresses neuroinflammation, limits oxidative cellular stress, and modulates microglial activity. In addition, it enhances endogenous cannabinoid signaling through the entourage effect. Therefore, when palmitoylethanolamide levels plummet during mania, the brain loses critical neuroprotective safeguards. This transient loss can exacerbate neurochemical dysregulation and heighten affective instability in vulnerable individuals.

Can circulating acylethanolamides serve as clinical biomarkers in psychiatry?

Circulating acylethanolamides show remarkable promise as state biomarkers for monitoring acute affective episodes in bipolar disorder. Because palmitoylethanolamide and oleoylethanolamide levels normalize upon remission, clinicians could theoretically track them to verify recovery objectively alongside clinical rating scales. Furthermore, identifying these lipid abnormalities highlights novel therapeutic possibilities. For instance, future therapies might utilize exogenous palmitoylethanolamide supplementation or degradation inhibitors to restore lipid homeostasis, thereby improving symptom management and overall treatment efficacy during acute manic presentations.

Disclaimer: This content is for informational and educational purposes only and should not be considered medical advice. Always consult a qualified healthcare professional regarding any medical condition or treatment. Refer to the latest local and national guidelines for clinical practice.

References

1. Özel S et al. The Relationship Between Manic Episodes and Serum Endocannabinoid Levels in Bipolar Disorder. Int J Neuropsychopharmacol. 2026 Nov 10. doi: undefined. PMID: 43007332.


2. Pacchiarotti I, et al. Plasma endocannabinoid levels in bipolar disorder: Differences between manic and euthymic states and the impact of cannabis use. J Affect Disord. 2026;361:122483.


3. Navarrete F, et al. Bipolar disorder and the endocannabinoid system. Br J Pharmacol. 2020;177(17):3851-3865.